Tweedy Browne's investment portfolio, as detailed in their Q2 2026 13F filing, reflects a strategic approach with a significant concentration in a few select equities. The total value of the portfolio reached an impressive $1.32 billion, distributed among 91 different holdings. A deep dive into the allocation reveals that a substantial portion, around 56%, is dominated by its five largest positions: CNH Industrial, Ionis Pharmaceuticals, Berkshire Hathaway, Coca-Cola FEMSA, and Johnson & Johnson. This concentration underscores the firm's conviction in these particular companies, even as they actively managed their positions through the quarter. The period saw a new addition with a stake in Zoetis, while another holding, Sealed Air, was exited following its acquisition. Furthermore, several existing major holdings, including CNH Industrial, Coca-Cola FEMSA, Johnson & Johnson, and Google, experienced continued trimming as the firm capitalized on previous gains, demonstrating an active and adaptive investment strategy.
During the second quarter of 2026, Tweedy Browne implemented several notable adjustments to its 13F portfolio. A significant development was the initiation of a new position in Zoetis, a global animal health company, which now accounts for approximately 3% of the portfolio. This new investment suggests a positive outlook on the animal healthcare sector or the specific prospects of Zoetis. Conversely, the firm completely divested its stake in Sealed Air, a packaging company, following its acquisition. This move is consistent with standard portfolio management practices when a holding undergoes a corporate transaction.
The quarter also saw continuous rebalancing within the firm's established core holdings. CNH Industrial (CNH), Coca-Cola FEMSA (KOF), Johnson & Johnson (JNJ), and Alphabet (GOOGL) were all subjected to further trimming. These adjustments are indicative of a disciplined approach to profit-taking, where positions are reduced after significant appreciation to realize gains and potentially reallocate capital. Despite these trims, Ionis Pharmaceuticals (IONS) and Berkshire Hathaway (BRK.B) maintained their status as core holdings, with only minimal adjustments made to their allocations. This stability highlights the firm's long-term confidence in these companies, viewing them as foundational elements of their investment strategy.
Moreover, a number of smaller positions within the portfolio also experienced reductions. This broader trimming across various holdings could signal a strategic move to streamline the portfolio, enhance focus on high-conviction assets, or free up capital for future opportunities. Such meticulous management of both large and small stakes illustrates Tweedy Browne’s active and value-oriented investment philosophy, which continuously seeks to optimize returns while managing risk through selective adjustments based on market conditions and company-specific developments.
In summary, Tweedy Browne's investment activities in Q2 2026 showcased a blend of continuity and tactical adjustments. The portfolio maintained a high level of concentration in its top five positions, reflecting a strong conviction in these select companies. The introduction of Zoetis as a new stake and the exit from Sealed Air due to acquisition were key transactional events. The ongoing reduction of holdings in CNH Industrial, Coca-Cola FEMSA, Johnson & Johnson, and Google was a consistent theme, indicating a strategy of harvesting gains. Meanwhile, the stability of Ionis Pharmaceuticals and Berkshire Hathaway underscored their enduring importance within the portfolio, signifying a well-considered and actively managed investment approach aimed at navigating market dynamics and maximizing long-term value.
